AAREYDRUGS (Small Cap) Share Target 2024, 2025 To 2039
|
Aarey Drugs & Pharmaceuticals Limited |
|||
|
Price: ₹56.64 | ||
| 52 Week Low: ₹37.35 52 Week High: ₹74.80 |
|||
| Market Capital: 159.67 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: AAREYDRUGS Share Price Target For 2024
- 1.1.1: AAREYDRUGS Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: AAREYDRUGS Share Price Target For 2025
- 1.2.1: AAREYDRUGS Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: AAREYDRUGS Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: AAREYDRUGS Brief Company Overview
- 4: AAREYDRUGS Financial Performance
- 4.0.1: Is AAREYDRUGS A Good Buy For Long Term?
To predict the AAREYDRUGS's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
AAREYDRUGS Share Price Target For 2024
The line chart displays the monthly closing prices of AAREYDRUGS with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for AAREYDRUGS shares in 2024, see the table below.
AAREYDRUGS Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 60.49 (+6.79%) | Technical Indicator: MA50 |
| 2024 Target 2 | 59.89 (+5.73%) | Fibonacci Extension Level 23.60% |
| 2024 Target 1 | 59.27 (+4.63%) | Price Action: 30 Oct 2024 High |
| Current Price | 56.64 | AAREYDRUGS's share price as of 24 Dec 2024 |
| Stop Loss 1 | 57.13 (+0.86%) | Price Action: 31 Oct 2024 Low |
| Stop Loss 2 | 56.3 (-0.61%) | Price Action: 29 Oct 2024 Low |
| Stop Loss 3 | 55.39 (-2.21%) | Price Action: 21 Nov 2024 High |
Short-Term Technical Outlook
Current Technical Position: AAREYDRUGS is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹58.96 serves as the nearest technical reference point.
Historical Returns: 3-month: -16.8% | 6-month: +25.53% | 1-year: +16.66%
AAREYDRUGS Share Price Target For 2025
The line chart displays the monthly closing prices of AAREYDRUGS with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for AAREYDRUGS shares in 2025, see the table below.
AAREYDRUGS Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 85.23 (+50.47%) | Price Action: Chart |
| 2025 Target 2 | 83.64 (+47.66%) | Fibonacci Extension Level 123.60% |
| 2025 Target 1 | 82.11 (+44.96%) | Fibonacci Extension Level 64.90% |
| Current Price | 56.64 | AAREYDRUGS's share price as of 24 Dec 2024 |
| Stop Loss 1 | 51.79 (-8.57%) | Price Action: Nov 2023 High |
| Stop Loss 2 | 51.25 (-9.52%) | Price Action: Apr 2022 High |
| Stop Loss 3 | 50.0 (-11.73%) | Price Action: Oct 2023 High |
Long-Term Technical Outlook
52-Week Range Analysis: AAREYDRUGS is currently trading at 51.5% of its 52-week range (₹37.35 - ₹74.8).
Long-Term Trend Analysis: The stock shows mixed long-term signals, trading near key moving averages.
Long-Term Performance: 1-year: +16.66% | 3-year: +37.28% | 5-year: NA
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
AAREYDRUGS Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹56.64 | ||
| 2024 | ₹62.92 | +11.08% | ₹63.86 |
| 2025 | ₹82.18 | +30.61% | ₹83.41 |
| 2026 | ₹99.87 | +21.52% | ₹101.37 |
| 2027 | ₹111.40 | +11.54% | ₹113.07 |
| 2028 | ₹129.68 | +16.4% | ₹131.63 |
| 2029 | ₹143.00 | +10.27% | ₹146.76 |
| 2030 | ₹165.56 | +15.77% | ₹168.31 |
| 2031 | ₹184.10 | +11.19% | ₹186.86 |
| 2032 | ₹191.79 | +4.17% | ₹194.67 |
| 2033 | ₹211.46 | +10.25% | ₹214.63 |
| 2034 | ₹223.08 | +5.49% | ₹232.97 |
| 2035 | ₹248.94 | +11.59% | ₹254.52 |
| 2036 | ₹268.33 | +7.78% | ₹272.35 |
| 2037 | ₹272.19 | +1.43% | ₹276.27 |
| 2038 | ₹293.25 | +7.73% | ₹297.65 |
| 2039 | ₹306.27 | +4.43% | ₹319.18 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
AAREYDRUGS Brief Company Overview
Company Overview: Aarey Drugs & Pharmaceuticals Limited Aarey Drugs & Pharmaceuticals Limited, established in 1990, is a reputable manufacturer and supplier of active pharmaceutical ingredients (APIs), intermediates, and specialty chemicals in India. The company has a...
diverse product portfolio: APIs: Metformin HCL, Mefenamic Acid, Doxophylline Chemicals and Solvents: Aromatic Chemicals, Chemical Acids, Chlor Alkalies, Glycols, Acetates, Esters Aarey Drugs & Pharmaceuticals Limited caters to pharmaceutical formulation manufacturers and exporters. The company is committed to providing high-quality products and services, making it a trusted name in the industry.AAREYDRUGS Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 159.67 Crore | Market valuation of AAREYDRUGS's shares. |
| Revenue (TTM) | 471.57 Crore | Total revenue generated by AAREYDRUGS over the past twelve months. |
| Net Income (TTM) | +5.19 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +0.56% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +1.1% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+149.1% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+71% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
23.61 | Company's total debt divided by total shareholder equity. |
| Total Debt | 31.35 Crore | Sum of AAREYDRUGS's current & long-term financial obligations. |
| Total Cash | 2.89 Crore | Total amount of liquid funds available to AAREYDRUGS. |
| Beta | 0.92 | Beta is less than 1 indicating that the AAREYDRUGS's price is less volatile than the market. |
Is AAREYDRUGS A Good Buy For Long Term?
AAREYDRUGS, a small-cap stock with a market capitalization of ₹159.67 crore, shows mixed signals for long-term investment. While its revenue (₹471.57 crore TTM) is substantial, the net profit margin of 1.1% is low. The significant revenue growth of 149.1% QoQ is positive, but a 71% YoY increase in earnings needs further investigation to confirm sustainability. High debt (₹31.35 crore) against low cash reserves (₹2.89 crore) is a concern. Past performance (33.38% return in the last 12 months) is impressive, but the 0% returns over 3 and 5 years raise red flags. Therefore, AAREYDRUGS is an average buy at best; further due diligence is crucial before considering a long-term investment.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
